Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study.
The effect of dimethyl fumarate (Tecfidera™) on lymphocyte counts: A potential contributor to progressive multifocal leukoencephalopathy risk.
Myelin Oligodendrocyte Glycoprotein-Associated Pediatric Central Nervous System Demyelination: Clinical Course, Neuroimaging Findings, and Response to Therapy.
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.
Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
Therapeutic effects of systemic administration of chaperone αB-crystallin associated with binding proinflammatory plasma proteins.
Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT.
Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial.
Genes associated with T helper 17 cell differentiation and function.
Primary results of DECIDE: a randomized, double-blind, double-dummy, active-controlled trial of daclizumab HYP vs. Interferon β-1a in RRMS patients
[Pharmacoeconomic analysis of the efficacy of natalizumab in relapsing-remitting multiple sclerosis].
Relationship between disease-modifying therapy and depression in multiple sclerosis.
The Brain as a Target of Inflammatory Processes
Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis.
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis.
Rituximab does not reset defective early B cell tolerance checkpoints.
Multiple sclerosis: pathogenesis and treatment.
MSGene
Episode 19 with Dr. Samuel Ludwin on treating MS subtypes
Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.
Firategrast
Dimethyl fumarate attenuates experimental autoimmune neuritis through the nuclear factor erythroid-derived 2-related factor 2/hemoxygenase-1 pathway by altering the balance of M1/M2 macrophages.
Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients.

Pages